9-valent human papillomavirus vaccine (Gardasil 9) - 3 doses + 9-valent human papillomavirus vaccine (Gardasil 9) - 2 doses + 9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose
Phase 3UNKNOWN 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Human Papillomavirus Vaccine
Conditions
Human Papillomavirus Vaccine
Trial Timeline
Sep 14, 2019 → Jun 1, 2024
NCT ID
NCT03832049About 9-valent human papillomavirus vaccine (Gardasil 9) - 3 doses + 9-valent human papillomavirus vaccine (Gardasil 9) - 2 doses + 9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose
9-valent human papillomavirus vaccine (Gardasil 9) - 3 doses + 9-valent human papillomavirus vaccine (Gardasil 9) - 2 doses + 9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose is a phase 3 stage product being developed by Merck for Human Papillomavirus Vaccine. The current trial status is unknown. This product is registered under clinical trial identifier NCT03832049. Target conditions include Human Papillomavirus Vaccine.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03832049 | Phase 3 | UNKNOWN |
Competing Products
20 competing products in Human Papillomavirus Vaccine